#TITLE_ALTERNATIVE#

• Main Author: NADHIF NIM: 20716034, NABILAH
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/29451
• Institution: Institut Teknologi Bandung

Neutropenia as the side effects of chemotherapy is a common complication it happens <br /> <br /> in approximately 20-40% patients with solid tumor and 50-70% in patients with <br /> <br /> hematological malignancy. Neutropenia is defined as an Absolute Neutrofil Count <br /> <br /> (ANC) of less than 1500/mm <br /> <br /> 3 <br /> <br /> . There are two granulocyte colony-stimulating factor <br /> <br /> (G-CSF) recommended to be used for the treatment of neutropenia at RSUD Cibabat <br /> <br /> Cimahi that are filgrastim and lenograstim. This study aimed to evaluate the <br /> <br /> effectiveness of use of filgrastim and lenograstim in achieving ANC recovery time in <br /> <br /> breast cancer patients at RSUD Cibabat Cimahi. The study was conducted by looking <br /> <br /> at the effect of filgrastim and lenograstim in achieving ANC recovery with age, IMT, <br /> <br /> chemotherapy regimen, cancer stage, cycle of chemotherapy and grade neutropenia <br /> <br /> as variables. A retrospective cohort design was applied in this study, using data from <br /> <br /> medical record during the period of June 2016 until March 2018. In that period, 200 <br /> <br /> incidences of neutropenia were found, 135 incidences fulfilling inclusion and <br /> <br /> exclusion criteria. A total of 38 patients (61 incidences) treated with filgrastim, and <br /> <br /> 50 patients (74 incidences) treated with lenograstim. The result showed that there <br /> <br /> was a very significant ANC recovery (p<0.01) on the neutropenia treatment that uses <br /> <br /> filgrastim or lenograstim (in the filgrastim-treated group, ANC increased from <br /> <br /> 1210.28±317.48/mm <br /> <br /> 3 <br /> <br /> to 9988.48±6555.80/mm <br /> <br /> 3 <br /> <br /> , that in lenograstim-treated group, <br /> <br /> ANC is increased from 1248.01±277.47/mm <br /> <br /> 3 <br /> <br /> to 9982.38±6250.69/mm <br /> <br /> 3 <br /> <br /> ). Cox <br /> <br /> Regression analysis revealed, that in lenograstim-treated group, the ANC recovery <br /> <br /> time was significantly associated with IMT 18.5-24.9 kg/m <br /> <br /> 2 <br /> <br /> (p=0.075) and the first <br /> <br /> cycle of chemotherapy (p=0.088). In the filgrastim-treated group, the ANC recovery <br /> <br /> time was significantly associated with stage 2b of cancer (p=0.059) and stage 3a of <br /> <br /> cancer (p=0.052). The higher the grade of neutropenia, the more time are needed to <br /> <br /> reach ANC recovery in either the filgrastim or lenograstim group. Statistically, there <br /> <br /> is no significant difference in duration of ANC recovery between neutropenia <br /> <br /> treatments using filgrastim or lenograstim in breast cancer patients at RSUD Cibabat <br /> <br /> Cimahi. This data indicates that filgrastim and lenograstim have the same potential <br /> <br /> in achieving ANC recovery. <br />